Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Abstract Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane conductance regulator modulator, which has shown efficacy in CF patients (≥6 years) with ≥1 Phe508del mutation and a minimal function mutation. In October 2019, ETI became available on compassionate use basis for...

Full description

Saved in:
Bibliographic Details
Main Authors: Renate Kos (Author), Anne H. Neerincx (Author), Dominic W. Fenn (Author), Paul Brinkman (Author), Rianne Lub (Author), Steffie E. M. Vonk (Author), Jolt Roukema (Author), Monique H. Reijers (Author), Suzanne W. J. Terheggen‐Lagro (Author), Josje Altenburg (Author), Christof J. Majoor (Author), Lieuwe D. Bos (Author), Eric G. Haarman (Author), Anke H. Maitland‐van der Zee (Author), the Amsterdam Mucociliary Clearance Disease (AMCD) (Author)
Format: Book
Published: Wiley, 2022-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items